Octagon Capital Advisors LP Unicycive Therapeutics, Inc. Put Options Transaction History

Octagon Capital Advisors LP

  • $263 Million
  • Q2 2025

Put Options

0 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
No transaction found.

Others Institutions Holding UNCY

# of Institutions
4
Shares Held
93.1K
Call Options Held
0
Put Options Held
0
View Full List

About Unicycive Therapeutics, Inc.

UNCY Quotes by TradingView
  • Ticker UNCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 15,052,500
  • Market Cap $64.9M
  • Description
  • Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...
More about UNCY
Track This Portfolio

Track Octagon Capital Advisors LP Portfolio

Follow Octagon Capital Advisors LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Octagon Capital Advisors LP, based on Form 13F filings with the SEC.

News

Stay updated on Octagon Capital Advisors LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email